This segment focuses on the research and development of novel therapeutics for liver and metabolic diseases, with a primary focus on non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Research and development activities include the clinical trials of Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, currently in Phase IIb clinical trials for NASH. The segment also includes the development of MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb clinical trials for type 2 diabetes and NASH. Technologies and methodologies used include protein engineering, antibody development, and clinical trial design. The patient impact is significant, as NASH and type 2 diabetes affect millions globally, and the segment aims to address unmet medical needs. Market positioning is strengthened through collaborations with major pharmaceutical companies like Merck. Future opportunities include expanding the pipeline to address other liver diseases and metabolic disorders. Regulatory and clinical aspects are crucial, with a focus on obtaining FDA approval for the lead product candidates. Partnerships with Merck and other strategic partners are essential for advancing the development and commercialization of these therapies.

This segment is dedicated to the discovery and development of innovative medicines for retinal diseases, including geographic atrophy. The primary research and development activity involves NGM621, an antibody currently in Phase II clinical trials for the treatment of geographic atrophy. The segment utilizes antibody engineering and clinical trial methodologies to develop targeted therapies. The patient impact is substantial, as geographic atrophy is a leading cause of vision loss. Market positioning is enhanced through a collaboration agreement with Merck & Co., Inc., focusing on the development of novel medicines for unmet patient needs in retinal diseases. Future opportunities include expanding the pipeline to address other retinal conditions. Regulatory and clinical aspects are critical, with a focus on obtaining regulatory approvals for the lead product candidates. Partnerships with Merck are essential for advancing the development and commercialization of these therapies.

This segment focuses on the development of novel therapeutics for advanced solid tumors. Research and development activities include NGM120, an antagonist antibody that binds GFRAL, currently in Phase 1/2 clinical trials, and NGM707 and NGM438, also in Phase 1/2 for the treatment of advanced solid tumors. The segment utilizes antibody engineering and clinical trial methodologies to develop targeted cancer therapies. The patient impact is significant, as it addresses unmet needs in advanced solid tumors. Market positioning is enhanced through collaborations and partnerships. Future opportunities include expanding the pipeline to address other cancer types and indications. Regulatory and clinical aspects are crucial, with a focus on obtaining regulatory approvals for the lead product candidates. Partnerships with strategic partners are essential for advancing the development and commercialization of these therapies.